BTK and diffuse large B-cell lymphoma: Based on the activity observed in DLBCL and MCL cell lines, we also tested the compound in two marginal zone lymphoma (MZL) cell lines (Karpas1718 and VL51) and their derivatives with acquired resistance to PI3K inhibitors, BTK inhibitors, and BCL2 inhibitors [29,30,31,32].